Reducing the risk of cardiovascular disease remains a major target in people with type 2 diabetes mellitus. While the effect of strict glycaemic control on the risk of cardiovascular disease remains a matter of debate, more emphasis has been placed on the safety and potential cardiovascular protection of glucose-lowering agents.
Anticoagulant drugs are used to prevent and treat venous and arterial thrombosis — cardiovascular diseases that combined are the leading cause of death in the world. This poster contains information on unfractionated heparin, low-molecular-weight heaprins, pentasaccharide, vitamin K antanognists, non-vitamin K antagonist oral anticoagulants (NOACs), and novel drug targets.
The pioneering of transcatheter coronary balloon angioplasty by Andreas Grüntzig in 1977 has undoubtedly had an important role in reducing the morbidity and mortality of patients with obstructive coronary artery disease. Percutaneous coronary intervention has become one of the most commonly performed medical procedures worldwide, and balloon angioplasty is now the dominant mechanism of revascularization in patients with peripheral arterial disease.
Disorders of plasma lipid and lipoprotein metabolism are well recognized as causative factors in the development of atherosclerotic cardiovascular disease. The rational management of such disorders requires an understanding of the factors that regulate plasma lipid metabolism and how abnormalities of such factors lead to dyslipidaemia.